Revolutionizing Solid Tumor Therapeutics Through TCR Therapy

TCR based innovative therapies have demonstrated promising clinical results, showcasing their unique advantages and distinctive potential in addressing solid tumors. Further approaches and strategies for optimal efficacy and safety are being investigated and evaluated to overcome:

1. Tumor heterogeneity.

2. Unspecificity and off-target toxicity.

3. Tumor microenvironment and exhaustion.

4. Limited expansion and persistence.SCG’s proprietary TCR platform technologies enable the new generation TCR-T products with competitive advantage and differentiation, which has been translated into clinical development across China, US and Southeast Asia with its leading candidate SCG101 for HBV-related HCC patients.

‍